BIO compared with LAZ: revenue, margins and what each company keeps, and the suppliers and customers both name

BIOBio-Rad Laboratories, Inc.

Mkt capRevenueRevenue

LAZLazard, Inc.

Mkt capRevenueRevenue

Compare

BIOBio-Rad Laboratories, Inc.

LAZLazard, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

BIO1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+4.50%—

LAZ2 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±9.5%▼−0.19%×0.02

Q2 FY26—▲+3.02%—

= impliedBIO realized, solidLAZ realized, hatchedOne scale, both sides: full bar = 10%× = |realized| ÷ impliedSource: market data

BIOBio-Rad Laboratories, Inc.

372.18· pre 372.18· delayed

Mkt cap$10.0BRevenue$651MQ2 FY26Revenue$2.6BFY25

LAZLazard, Inc.

38.37· pre 38.37· delayed

Pre-marketOct 30 '26delayed

Mkt cap$4.2BRevenue$836MQ3 FY26Revenue$3.2BFY25

Compare

Pre-marketOct 30 '26delayed

BIOBio-Rad Laboratories, Inc.

LAZLazard, Inc.

372.18pre 372.18delayed

Price

38.37pre 38.37delayed

$10.0B

Mkt cap

$4.2B

Q2 FY26$651M

Revenue

$836MQ3 FY26

FY25$2.6B

Revenue

$3.2BFY25

BIO372.18vsLAZ38.37Pre-marketOct 30 '26delayed